Augmentin Dosage for a 23kg Child with Otitis Media
For a 23kg child with otitis media, the recommended dose of Augmentin is 80-90 mg/kg/day of the amoxicillin component, which equals approximately 1840-2070 mg/day divided into two doses (920-1035 mg twice daily). 1, 2
Dosage Calculation
Based on the child's weight of 23kg, the appropriate dosage calculation is:
High-dose amoxicillin-clavulanate is preferred for otitis media to overcome resistant strains of S. pneumoniae 3
The FDA-approved formulation for children with otitis media is based on the amoxicillin component, with a 14:1 ratio of amoxicillin to clavulanate to minimize gastrointestinal side effects 2, 1
Formulation Selection
For a 23kg child, the high-dose amoxicillin/clavulanate suspension (typically 600 mg/5 mL or 400 mg/5 mL) is recommended 1, 2
The twice-daily regimen is preferred over three-times-daily dosing as it:
Treatment Duration
The recommended duration of therapy for acute otitis media is 10 days 2, 3
Children should begin to show clinical improvement within 24-48 hours of starting therapy 1
If no improvement is seen within 48-72 hours, reassessment is necessary to confirm the diagnosis and consider changing the antibiotic 1
Special Considerations
Amoxicillin-clavulanate is particularly indicated when:
For children with vomiting or inability to tolerate oral medication, a single 50 mg/kg dose of ceftriaxone (IV or IM) can be given initially 3
Monitoring and Side Effects
The most common adverse effect is diarrhea, occurring in approximately 7-14% of patients on the twice-daily regimen 4, 2
The twice-daily formulation has a better gastrointestinal tolerance profile than the three-times-daily formulation 2, 4
Pain management should be addressed regardless of antibiotic therapy 1
Clinical Efficacy
High-dose amoxicillin-clavulanate has shown superior efficacy in eradicating S. pneumoniae (96%) from the middle ear compared to other antibiotics 3
Clinical success rates of approximately 94% have been reported with the twice-daily regimen 4
Amoxicillin-clavulanate is effective against the main pathogens of AOM, including penicillin-resistant S. pneumoniae, β-lactamase-producing H. influenzae, and M. catarrhalis 6, 7